IL17A and breast carcinoma: A previous study (Patin et al., 2018) has shown that type I IFN receptor signaling controls the activity of protumoral IL17A-producing γδT cells in breast cancer, which is consistent with the high expression of IFNG, the high proportion of the γδT cells in the pCR group, and the enriched IL-17 signaling pathway in the present study.